BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Domènech E, Mañosa M, Cabré E. An overview of the natural history of inflammatory bowel diseases. Dig Dis 2014;32:320-7. [PMID: 24969275 DOI: 10.1159/000358131] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Domènech E, Gisbert JP. Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2016;39:677-86. [DOI: 10.1016/j.gastrohep.2015.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
4 Gordillo J, Zabana Y, Garcia-Planella E, Mañosa M, Llaó J, Gich I, Marín L, Szafranska J, Sáinz S, Bessa X, Cabré E, Domènech E. Prevalence and risk factors for colorectal adenomas in patients with ulcerative colitis. United European Gastroenterol J 2018;6:322-30. [PMID: 29511562 DOI: 10.1177/2050640617718720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Domènech E, López-sanromán A, Nos P, Vera M, Chaparro M, Esteve M, Gisbert JP, Mañosa M. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn. Gastroenterología y Hepatología 2017;40:472-83. [DOI: 10.1016/j.gastrohep.2017.05.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
6 Heidari M, Pouya S, Baghaei K, Aghdaei HA, Namaki S, Zali MR, Hashemi SM. The immunomodulatory effects of adipose-derived mesenchymal stem cells and mesenchymal stem cells-conditioned medium in chronic colitis. J Cell Physiol. 2018;233:8754-8766. [PMID: 29797577 DOI: 10.1002/jcp.26765] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
7 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Sebastian S, Myers S, Argyriou K, Martin G, Los L, Fiske J, Ranjan R, Cooper B, Goodoory V, Ching HL, Jayasooriya N, Brooks J, Dhar A, Shenoy AH, Limdi JK, Butterworth J, Allen PB, Samuel S, Moran GW, Shenderey R, Parkes G, Lobo A, Kennedy NA, Subramanian S, Raine T. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019;50:675-683. [PMID: 31456297 DOI: 10.1111/apt.15456] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
9 Wu X, Liang TY, Wang Z, Chen G. The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review. Med Gas Res 2021;11:66-71. [PMID: 33818446 DOI: 10.4103/2045-9912.311497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wang FY, Chi CC. Association of rosacea with inflammatory bowel disease: A MOOSE-compliant meta-analysis. Medicine (Baltimore) 2019;98:e16448. [PMID: 31593075 DOI: 10.1097/MD.0000000000016448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 Olmedo-Martín RV, González-Molero I, Olveira G, Amo-Trillo V, Jiménez-Pérez M. Vitamin D in Inflammatory Bowel Disease: Biological, Clinical and Therapeutic Aspects. Curr Drug Metab 2019;20:390-8. [PMID: 31109269 DOI: 10.2174/1389200220666190520112003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Kim JT, Napier DL, Kim J, Li C, Lee EY, Weiss HL, Wang Q, Evers BM. Ketogenesis alleviates TNFα-induced apoptosis and inflammatory responses in intestinal cells. Free Radic Biol Med 2021;172:90-100. [PMID: 34087430 DOI: 10.1016/j.freeradbiomed.2021.05.032] [Reference Citation Analysis]
13 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
14 Couvineau A, Voisin T, Nicole P, Gratio V, Abad C, Tan YV. Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases. Front Endocrinol (Lausanne) 2019;10:709. [PMID: 31695678 DOI: 10.3389/fendo.2019.00709] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
15 Anderson A, Cherfane C, Click B, Ramos-Rivers C, Koutroubakis IE, Hashash JG, Babichenko D, Tang G, Dunn M, Barrie A, Proksell S, Dueker J, Johnston E, Schwartz M, Binion DG. Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. Inflamm Bowel Dis 2021:izab031. [PMID: 33693659 DOI: 10.1093/ibd/izab031] [Reference Citation Analysis]
16 van Wassenaer EA, de Voogd FAE, van Rijn RR, van Der Lee JH, Tabbers MM, van Etten-Jamaludin FS, Gecse KB, Kindermann A, De Meij TGJ, D'haens GR, Benninga MA, Koot BGP. Diagnostic Accuracy of Transabdominal Ultrasound in Detecting Intestinal Inflammation in Paediatric IBD Patients-a Systematic Review. J Crohns Colitis 2019;13:1501-9. [PMID: 31329839 DOI: 10.1093/ecco-jcc/jjz085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Jairath V. Hyperbaric Oxygen for Hospitalized patients with Ulcerative Colitis. American Journal of Gastroenterology 2018;113:1432-4. [DOI: 10.1038/s41395-018-0224-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Garcia-Planella E, Mañosa M, Cabré E, Marín L, Gordillo J, Zabana Y, Boix J, Sáinz S, Domènech E. Fecal Calprotectin Levels Are Closely Correlated with the Absence of Relevant Mucosal Lesions in Postoperative Crohn's Disease. Inflamm Bowel Dis 2016;22:2879-85. [PMID: 27824646 DOI: 10.1097/MIB.0000000000000960] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
19 Palacio FGM, de Souza LMP, Moreira JPL, Luiz RR, de Souza HSP, Zaltman C. Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis. BMC Gastroenterol 2021;21:192. [PMID: 33906627 DOI: 10.1186/s12876-021-01781-x] [Reference Citation Analysis]
20 Suau R, Pardina E, Domènech E, Lorén V, Manyé J. The complex relationship between microbiota, immune response and creeping fat in Crohn's disease. J Crohns Colitis 2021:jjab159. [PMID: 34528668 DOI: 10.1093/ecco-jcc/jjab159] [Reference Citation Analysis]
21 Cañete F, Mañosa M, Casanova MJ, González-sueyro RC, Barrio J, Bermejo F, Nos P, Iglesias-flores E, García-planella E, Pérez-calle JL, Vicente R, Vera M, Ramos L, Rivero M, De Francisco R, Montserrat A, Benítez O, Navarro P, Taxonera C, Hinojosa E, Márquez-mosquera L, Navarro-llavat M, Ramírez-de la Piscina P, Gomollón F, Rodríguez-alonso L, Núñez-alonso A, Fernández-salazar L, Almela P, Ríos León R, De Castro L, Gisbert JP, Ricart E, Cabré E, Domènech E; ENEIDA registry by GETECCU. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry. Inflammatory Bowel Diseases 2019;25:1862-70. [DOI: 10.1093/ibd/izz084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
22 Garcia-planella E, Mañosa M, Chaparro M, Beltrán B, Barreiro-de-acosta M, Gordillo J, Ricart E, Bermejo F, García-sánchez V, Piqueras M, Llaó J, Gisbert JP, Cabré E, Domènech E; On behalf of the PRECUCAL study group Investigators. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. Scandinavian Journal of Gastroenterology 2018;53:152-7. [DOI: 10.1080/00365521.2017.1410219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
23 Sheng X, Liu D, Gamage SK, Luo Y, Viennois E, Merlin D, Iyer SS. Point-of-Care Monitoring of Colitis Using Intestinal Alkaline Phosphatase in Inflammatory Bowel Disease. ACS Sens 2021;6:698-702. [PMID: 33635063 DOI: 10.1021/acssensors.0c02177] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Cañete F, Mañosa M, Pérez-Martínez I, Barreiro-de Acosta M, González-Sueyro RC, Nos P, Iglesias-Flores E, Gutiérrez A, Bujanda L, Gordillo J, Ríos León R, Casanova MJ, Villoria A, Rodríguez-Lago I, López Serrano P, García-Herola A, Ramírez-de la Piscina P, Navarro-Llavat M, Taxonera C, Barrio J, Ramos L, Navarro P, Benítez-Leiva O, Calafat M, Domènech E; INFLIRECU study. Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis. Clin Transl Gastroenterol 2020;11:e00218. [PMID: 32955190 DOI: 10.14309/ctg.0000000000000218] [Reference Citation Analysis]
25 Messal N, Fernandez N, Dayot S, Gratio V, Nicole P, Prochasson C, Chantret I, LeGuilloux G, Jarry A, Couvelard A, Tréton X, Voisin T, Ogier-Denis E, Couvineau A. Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A. Biochim Biophys Acta Mol Basis Dis 2018;1864:3618-28. [PMID: 30251681 DOI: 10.1016/j.bbadis.2018.08.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
26 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]